PDF(Pubmed)
Abstract：
The rising global morbidity and mortality rates of non-small cell lung cancer (NSCLC) underscore the urgent need for more effective treatments. Current therapeutic modalities-including surgery, radiotherapy, chemotherapy, and targeted therapy-face several limitations. Recently, Astragalus membranaceus, a traditional Chinese medicine (TCM), has captured significant attention due to its broad pharmacological properties, such as immune regulation, anti-inflammatory effects, and the modulation of reactive oxygen species (ROS) and enzyme activities. This review delivers a comprehensive summary of the most recent advancements and ongoing applications of Astragalus membranaceus in NSCLC treatment, underlining its potential for integration into existing treatment protocols. It also highlights essential areas for future research, including the elucidation of its molecular mechanisms, optimization of dosage and administration, and evaluation of its efficacy and safety alongside standard therapies, all of which could potentially improve therapeutic outcomes for NSCLC patients.
摘要：
非小细胞肺癌（NSCLC）的全球发病率和死亡率上升，凸显了对更有效治疗的迫切需要。目前的治疗方式-包括手术，放射治疗,化疗,和靶向治疗面临几个局限性。最近,黄芪，中药（TCM），由于其广泛的药理特性而引起了极大的关注，如免疫调节，抗炎作用，以及活性氧（ROS）和酶活性的调节。本文综述了黄芪在NSCLC治疗中的最新进展和正在进行的应用。强调其整合到现有治疗方案的潜力。它还强调了未来研究的重要领域，包括阐明其分子机制，优化剂量和给药，并与标准疗法一起评估其疗效和安全性，所有这些都可能改善NSCLC患者的治疗结局.
